Current evidence demonstrated that cancer testis antigens (CTA) such as pituitary tumor transforming gene 1 (PTTG1), A-kinase anchor protein 4 (AKAP4), and sperm protein 17 (SP17) are potential immunotherapeutic targets in NSCLC [12, 13]. This evidence concerns the gene AKAP4 and cancer.